Molecular aspects of azole antifungal action and resistance

被引:75
作者
Lamb, D [1 ]
Kelly, D [1 ]
Kelly, S [1 ]
机构
[1] Aberystwyth Univ, Cytochrome P450 Res Grp, AberBioctr, Aberystwyth SY23 3DA, Dyfed, Wales
关键词
D O I
10.1054/drup.1999.0112
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
During the past three decades azole compounds have been developed as medical and agricultural agents to combat fungal diseases. During the 1980s they were introduced as orally active compounds in medicine and the number of such azole drugs is likely to expand in the near future. They represent a successful strategy for antifungal development, but as the incidence of fungal infection has increased coupled to prolonged use of the drugs, the (almost) inevitable emergence of resistance has occurred. This was after resistance had already been encountered as a serious problem in the field, where a larger number of azole fungicides had been employed commercially. In this review the molecular basis of how azoles work is discussed together with how fungi overcome the inhibitory effect of these compounds: through alterations in the primary target molecule (cytochrome P4505 I; Erg I Lp; sterol 14 alpha-demethylase); through drug efflux mechanisms and through a suppressor mechanism allowing growth on 14-methylated sterols. (C) 1999 Harcourt Publishers Ltd.
引用
收藏
页码:390 / 402
页数:13
相关论文
共 88 条
[1]   AP1-mediated multidrug resistance in Saccharomyces cerevisiae requires FLR1 encoding a transporter of the major facilitator superfamily [J].
Alarco, AM ;
Balan, I ;
Talibi, D ;
Mainville, N ;
Raymond, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (31) :19304-19313
[2]   POSSIBLE ROLE FOR CYTOCHROME-P-450 DURING BIOSYNTHESIS OF ZYMOSTEROL FROM LANOSTEROL BY SACCHAROMYCES-CEREVISIAE [J].
ALEXANDER, KT ;
MITROPOULOS, KA ;
GIBBONS, GF .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1974, 60 (01) :460-467
[3]  
Aoyama Y, 1996, J BIOCHEM-TOKYO, V119, P926
[4]  
AOYAMA Y, 1983, J BIOL CHEM, V258, P9040
[5]   Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450 [J].
Asai, K ;
Tsuchimori, N ;
Okonogi, K ;
Perfect, JR ;
Gotoh, O ;
Yoshida, Y .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1163-1169
[6]  
BALLARD SA, 1990, J MED VET MYCOL, V28, P335
[7]  
BALZI E, 1994, J BIOL CHEM, V269, P2206
[8]   CHARACTERIZATION OF A CYTOCHROME-P450 DEFICIENT MUTANT OF CANDIDA-ALBICANS [J].
BARD, M ;
LEES, ND ;
BARBUCH, RJ ;
SANGLARD, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1987, 147 (02) :794-800
[9]   Characterization and catalytic properties of the sterol 14α-demethylase from Mycobacterium tuberculosis [J].
Bellamine, A ;
Mangla, AT ;
Nes, WD ;
Waterman, MR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (16) :8937-8942
[10]  
BORELLI D, 1987, REV INFECT DIS, V9, pS57